Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Severe COVID-19 with Pulmonary Hyperinflammation
NCT04377750Phase 4
Key facts
- Status
- Unknown
- Start
- Apr 2020
- Primary completion
- Apr 2020
- Countries
- 1
- Sponsor
- Hadassah Medical Organization
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Drugs
- tocilizumab
- Conditions
- COVID-19 pneumonia
01
Overview
Phase 4, randomised, open-label trial of tocilizumab in COVID-19 pneumonia, sponsored by Hadassah Medical Organization. Primary endpoint: One-month mortality rate at 1 month. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Adults with PCR-confirmed SARS-CoV-2, acute respiratory failure, and radiographic pneumonia requiring >50% oxygen or recently intubated.
04
Endpoints
Primary
One-month mortality rate
Secondary
Duration of hospitalization
Beyond the preview
Go deeper on NCT04377750.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377750.